SEC Form 4 · accession 0001209191-17-038895
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jun 8, 2017
Accepted (ET)
Jun 9, 2017 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 8, 2017 | M | 2,941 | — | A | 284,088 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common Stock | holding | — | — | — | 64,525 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF1 | — | Jun 8, 2017 | M | 2,941 | D | — | — | Common Stock | 2,941 | 0 | D |
Explanation of responses
- F1Each deferred stock unit represents one share of common stock and converted into common stock upon the termination of Dr. Boger's service on our board of directors on 06/08/2017.